Rob Salmon

369 posts

Rob Salmon

Rob Salmon

@salmon_rob

Dad and husband to my wonderful family. Former tech exec, NetApp, Cohesity. Golfer. Living w/ multiple myeloma. Patient advocate.

Katılım Eylül 2012
632 Takip Edilen1.4K Takipçiler
Rob Salmon retweetledi
Adam C Palmer
Adam C Palmer@ac_palmer·
Sometimes cancer treatments are subject to hype, but here’s an advance that’s been understated: Combining a T-cell engager antibody with daratumumab allowed >80% of people with relapsed or refractory multiple myeloma to go years without progression. Might be *permanent* control
Adam C Palmer tweet media
Blood Cancer United@BloodCancerUtd

Encouraging news for patients living with multiple myeloma. The FDA has expanded the use of a combination treatment for multiple myeloma, allowing it to be used earlier when the disease returns or starts to worsen. “This approval is due to years of scientific progress and will be a meaningful improvement for many patients,” says Dr. Gruenbaum. Learn more: bloodcancerunited.org/resources/news…

English
11
70
354
89.2K
Rob Salmon retweetledi
Samuel Hume
Samuel Hume@DrSamuelBHume·
How outcomes in relapsed/refractory multiple myeloma changed, from 1986 to 2026
Samuel Hume tweet media
English
24
162
756
232.1K
Rob Salmon retweetledi
Doog
Doog@doogadoo11·
Damn. I’m sure there’s a U.S. / Iran analogy in there somewhere.
English
598
1.6K
11.6K
1.2M
Rob Salmon retweetledi
Vincent Rajkumar
Vincent Rajkumar@VincentRK·
China has now surpassed all other countries in number of new oncology clinical trials launched each year, AND also number of novel active substances (NAS) for cancers launched. @IQVIA_global iqvia.com/library/videos…
Vincent Rajkumar tweet media
English
13
139
422
214K
Rob Salmon retweetledi
Nathan Punwani
Nathan Punwani@npunwani·
We’ve come a long way in multiple myeloma #EBMT26
Nathan Punwani tweet media
English
0
3
27
2.7K
Rob Salmon
Rob Salmon@salmon_rob·
Patty is running the Tokyo Marathon on March 1st. This marathon will complete the six majors in the world for Patty: Boston, Chicago, New York, Berlin, London, and Tokyo. How cool is that! She is running for the Multiple Myeloma Research Foundation (MMRF). MMRF is a great organization focused on helping patients and caregivers on the myeloma journey. If you are so inclined, please visit Patty’s page and consider a donation to the MMRF. give.themmrf.org/psalmon @MMRFTeam4Cures @theMMRF
English
3
0
4
168
Rob Salmon retweetledi
Jim Omel
Jim Omel@IMFjimMYELOMA·
Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape medpagetoday.com/meetingcoverag… Four patients with in-vivo induced CAR-T cell therapy.
English
0
2
4
498
Rob Salmon retweetledi
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽@Rfonsi1·
It is time to change the nomenclature for MM treatment regimen acronyms. If it involves a Bispecific or CART, we need to add -Ig at the end to recognize the need for: - Proactive - Sufficient - Ongoing until needed - Closely monitored IgG replacement. Saying that an "x% of patients were replaced" is not enough. When? To what level? etc. It should never go under 400 mg/dL, and probably higher. We need to account for the M-spike concentration in IgG MM. With CART and bispecifics we are using regardless. #ASH25RF #mmsm
English
3
9
45
7.6K
Rob Salmon
Rob Salmon@salmon_rob·
I appreciate the focus on infections as we see bispecific and car-t used more in front line. The possibility for less toxicity but more infections. A balancing act for sure but the impact on reducing myeloma burden is compelling.
Rahul Banerjee, MD, FACP@RahulBanerjeeMD

#ASH25 the most important part of tec-dara beyond its outstanding efficacy in MajesTEC-3… The combo can only be possible with appropriate infection prevention. 🚨 We now know - use primary IVIG prophylaxis with this and other BCMA bsAbs!

English
0
1
2
412
Rob Salmon retweetledi
Rakesh Popat
Rakesh Popat@DrRakeshPopat·
In-vivo BCMA CAR-T first in human trial. 3 patients all achieving MRD negativity. This could be revolutionary - no need for lymphodepletion chemo, no complicated cell manufacturing process and better memory T cell phenotype. Looking forward to more data esp safety #ASH25
Rakesh Popat tweet mediaRakesh Popat tweet mediaRakesh Popat tweet media
English
2
39
88
14.8K
Rob Salmon retweetledi
Vincent Rajkumar
Vincent Rajkumar@VincentRK·
Impressive. Bela-KPd in patients relapsing after CART in relapsed myeloma. #ASH25 @bdermanmd -Lower dose of Belantamab every 8 weeks — this is critical. -82% response rate -Median PFS 15 months
English
2
15
60
4.5K
Rob Salmon retweetledi
Samer Al Hadidi, MD,MS,FACP
Samer Al Hadidi, MD,MS,FACP@HadidiSamer·
#ASH25 #mmsm @ASH_hematology Oral myeloma- long term CARTITUDE-4 in standard risk patients @End_myeloma ✅ 80% progression-free & off treatment at 2.5 years ✅ 93% of 1-year responders remained progression-free at 2.5 years ✅ 100% of MRD-negative CR patients progression-free at 2.5 years ✅ No IEC-parkinsonism events, low non-relapse mortality
Samer Al Hadidi, MD,MS,FACP tweet mediaSamer Al Hadidi, MD,MS,FACP tweet mediaSamer Al Hadidi, MD,MS,FACP tweet mediaSamer Al Hadidi, MD,MS,FACP tweet media
English
0
21
45
4.5K

Keşfet

@IQVIA_global @MMRFTeam4Cures @theMMRF @IMFmyeloma @bdermanmd @ASH_hematology @End_myeloma @AlfredChung11